{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T12:15:06Z","timestamp":1794831306164,"version":"4.9.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,3,13]],"date-time":"2018-03-13T00:00:00Z","timestamp":1520899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1038\/s41416-018-0006-0","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T10:45:38Z","timestamp":1520592338000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours"],"prefix":"10.1038","volume":"118","author":[{"given":"Keith","family":"Dredge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd V.","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Lickliter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryn","family":"Bampton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Handley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Lankesheer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glynn","family":"Morrish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Millward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,13]]},"reference":[{"key":"6_CR1","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","volume":"17","author":"MA Postow","year":"2015","unstructured":"Postow, MA., Callahan, MK. & Wolchok, JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 17, 1974\u20131982 (2015).","journal-title":"J Clin Oncol"},{"key":"6_CR2","first-page":"418","volume":"5","author":"KM Kreamer","year":"2014","unstructured":"Kreamer, K. M. Immune checkpoint blockade: a new paradigm in treating advanced cancer. J. Adv. Pract. Oncol. 5, 418\u2013431 (2014).","journal-title":"J. Adv. Pract. Oncol."},{"key":"6_CR3","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/0008-5472.CAN-16-2379","volume":"77","author":"X Zhao","year":"2017","unstructured":"Zhao, X. & Subramanian, S. Intrinsic resistance of solid tumors to immune checkpoint blockade therapy. Cancer Res. 77, 817\u2013822 (2017).","journal-title":"Cancer Res."},{"key":"6_CR4","doi-asserted-by":"publisher","first-page":"3145742","DOI":"10.1155\/2017\/3145742","volume":"2017","author":"EJ Sayour","year":"2017","unstructured":"Sayour, E. J. & Mitchell, D. A. Manipulation of innate and adaptive immunity through cancer vaccines. J. Immunol. Res 2017, 3145742 (2017).","journal-title":"J. Immunol. Res"},{"key":"6_CR5","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447\u2013462 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"6_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty, G. L., Li, Y. & Long, K. B. Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert. Rev. Anticancer. Ther. 17, 175\u2013186 (2017).","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"6_CR7","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1158\/0008-5472.CAN-12-2731","volume":"73","author":"JB Mitchem","year":"2013","unstructured":"Mitchem, J. B. et al Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128\u20131141 (2013).","journal-title":"Cancer Res."},{"key":"6_CR8","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nrd.2016.111","volume":"15","author":"C Morrison","year":"2016","unstructured":"Morrison, C. Immuno-oncologists eye up macrophage targets. Nat. Rev. Drug. Discov. 15, 373\u2013374 (2016).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"6_CR9","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","volume":"74","author":"Y Zhu","year":"2014","unstructured":"Zhu, Y. et al CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 74, 5057\u20135069 (2014).","journal-title":"Cancer Res."},{"key":"6_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"6_CR11","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. L. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143\u2013158 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"6_CR12","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1007\/s10637-009-9245-5","volume":"28","author":"K Dredge","year":"2010","unstructured":"Dredge, K. et al The PG500 series: novel heparan sulfate mimetics as potent angiogenesis and heparanase inhibitors for cancer therapy. Invest. New Drugs 28, 276\u2013283 (2010).","journal-title":"Invest. New Drugs"},{"key":"6_CR13","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/bjc.2011.11","volume":"104","author":"K Dredge","year":"2011","unstructured":"Dredge, K. et al PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical models. Br. J. Cancer 104, 635\u2013642 (2011).","journal-title":"Br. J. Cancer"},{"key":"6_CR14","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1021\/jm201708h","volume":"55","author":"V Ferro","year":"2012","unstructured":"Ferro, V. et al Discovery of PG545: a highly potent and simultaneous inhibitor of angiogenesis, tumor growth, and metastasis. J. Med. Chem. 55, 3804\u20133813 (2012).","journal-title":"J. Med. Chem."},{"key":"6_CR15","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/0008-5472.CAN-13-2962","volume":"74","author":"I Boyango","year":"2014","unstructured":"Boyango, I. et al Heparanase cooperates with Ras to drive breast and skin tumorigenesis. Cancer Res. 74, 4504\u20134514 (2014).","journal-title":"Cancer Res."},{"key":"6_CR16","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1158\/1535-7163.MCT-12-1123","volume":"12","author":"KT Ostapoff","year":"2013","unstructured":"Ostapoff, K. T. et al PG545, an angiogenesis and heparanase inhibitor, reduces primary tumor growth and metastasis in experimental pancreatic cancer. Mol. Cancer Ther. 12, 1190\u20131201 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"6_CR17","unstructured":"Hermano E, et al. Macrophage polarization in pancreatic carcinoma: role of heparanase enzyme. J. Natl Cancer. Inst. 106, dju332 (2014)."},{"key":"6_CR18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1172\/JCI76566","volume":"126","author":"TV Brennan","year":"2016","unstructured":"Brennan, T. V. et al Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J. Clin. Invest. 126, 207\u2013219 (2016).","journal-title":"J. Clin. Invest."},{"key":"6_CR19","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.18632\/oncotarget.3214","volume":"6","author":"DB Jung","year":"2015","unstructured":"Jung, D.-B. et al The heparan sulfate mimetic PG545 interferes with Wnt\/\u03b2-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine. Oncotarget 6, 4992\u20135004 (2015).","journal-title":"Oncotarget"},{"key":"6_CR20","doi-asserted-by":"publisher","first-page":"33705","DOI":"10.18632\/oncotarget.5605","volume":"6","author":"S Mondal","year":"2015","unstructured":"Mondal, S. et al HSulf-1 deficiency dictates a metabolic reprograming of glycolysis and TCA cycle in ovarian cancer. Oncotarget 6, 33705\u201333719 (2015).","journal-title":"Oncotarget"},{"key":"6_CR21","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.neo.2016.12.001","volume":"19","author":"P Singh","year":"2017","unstructured":"Singh, P. et al The heparanase inhibitor PG545 attenuates colon cancer initiation and growth, associating with increased p21 expression. Neoplasia 19, 175\u2013184 (2017).","journal-title":"Neoplasia"},{"key":"6_CR22","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/j.ejca.2015.02.007","volume":"51","author":"B Winterhoff","year":"2015","unstructured":"Winterhoff, B. et al PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samples. Eur. J. Cancer 51, 879\u2013892 (2015).","journal-title":"Eur. J. Cancer"},{"key":"6_CR23","doi-asserted-by":"publisher","first-page":"e52175","DOI":"10.1371\/journal.pone.0052175","volume":"7","author":"E Hammond","year":"2012","unstructured":"Hammond, E., Brandt, R. & Dredge, K. PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model. PLoS ONE 7, e52175 (2012).","journal-title":"PLoS ONE"},{"key":"6_CR24","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.onc.1210911","volume":"27","author":"AM Krieg","year":"2008","unstructured":"Krieg, A. M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161\u2013167 (2008). 10.1038\/sj.onc.1210911.","journal-title":"Oncogene"},{"key":"6_CR25","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","volume":"14","author":"SR Hayman","year":"2012","unstructured":"Hayman, S. R., Leung, N., Grande, J. P. & Garovic, V. D. VEGF inhibition, hypertension, and renal toxicity. Curr. Oncol. Rep. 14, 285\u2013294 (2012).","journal-title":"Curr. Oncol. Rep."},{"key":"6_CR26","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/cvr\/cvv137","volume":"107","author":"CG McCarthy","year":"2015","unstructured":"McCarthy, C. G. et al Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. Cardiovasc. Res. 107, 119\u2013130 (2015).","journal-title":"Cardiovasc. Res."},{"key":"6_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1248\/bpb.34.120","volume":"34","author":"HY Kim","year":"2011","unstructured":"Kim, H. Y. et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol. Pharm. Bull. 34, 120\u2013127 (2011).","journal-title":"Biol. Pharm. Bull."},{"key":"6_CR28","doi-asserted-by":"publisher","first-page":"L552","DOI":"10.1152\/ajplung.00436.2003","volume":"287","author":"J Li","year":"2004","unstructured":"Li, J. et al CpG DNA-mediated immune response in pulmonary endothelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L552\u2013L558 (2004).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"6_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40425-017-0218-5","volume":"5","author":"PA Ott","year":"2017","unstructured":"Ott, P. A., Hodi, F. S., Kaufman, H. L., Wigginton, J. M. & Wolchok, J. D. Combination immunotherapy: a road map. J. Immunother. Cancer 5, 16 (2017).","journal-title":"J. Immunother. Cancer"},{"key":"6_CR30","doi-asserted-by":"publisher","first-page":"3347","DOI":"10.1172\/JCI80007","volume":"125","author":"S Shalapour","year":"2015","unstructured":"Shalapour, S. & Karin, M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J. Clin. Invest. 125, 3347\u20133355 (2015).","journal-title":"J. Clin. Invest."},{"key":"6_CR31","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/1078-0432.CCR-07-0050","volume":"13","author":"BG Molenkamp","year":"2007","unstructured":"Molenkamp, B. G. et al Intradermal CpG-B activates both plasmacytoid and myeloid dendritic cells in the sentinel lymph node of melanoma patients. Clin. Cancer Res. 13, 2961\u20132969 (2007).","journal-title":"Clin. Cancer Res."},{"key":"6_CR32","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1158\/1078-0432.CCR-14-0392","volume":"20","author":"DW Northfelt","year":"2014","unstructured":"Northfelt, D. W. et al A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma. Clin. Cancer Res. 20, 3683\u20133691 (2014).","journal-title":"Clin. Cancer Res."},{"key":"6_CR33","doi-asserted-by":"publisher","first-page":"3944","DOI":"10.1002\/cncr.24473","volume":"115","author":"JS Weber","year":"2009","unstructured":"Weber, J. S. et al Randomized phase 2\/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma. Cancer 115, 3944\u20133954 (2009).","journal-title":"Cancer"},{"key":"6_CR34","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2014.11.002","volume":"51","author":"MR Weihrauch","year":"2015","unstructured":"Weihrauch, M. R. et al Phase I clinical study of the toll-like receptor 9 agonist MGN1703 in patients with metastatic solid tumours. Eur. J. Cancer 51, 146\u2013156 (2015).","journal-title":"Eur. J. Cancer"},{"key":"6_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.critrevonc.2014.12.002","volume":"94","author":"B Wittig","year":"2015","unstructured":"Wittig, B., Schmidt, M., Scheithauer, W. & Schmoll, H.-J. MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: from bench to bedside. Crit. Rev. Oncol. Hematol. 94, 31\u201344 (2015).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"6_CR36","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1078-0432.CCR-14-2355","volume":"21","author":"P Johnson","year":"2015","unstructured":"Johnson, P. et al Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I study. Clin. Cancer Res. 21, 1321\u20131328 (2015).","journal-title":"Clin. Cancer Res."},{"key":"6_CR37","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1158\/1078-0432.CCR-10-2672","volume":"17","author":"C Zoglmeier","year":"2011","unstructured":"Zoglmeier, C. et al CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice. Clin. Cancer Res. 17, 1765\u20131775 (2011).","journal-title":"Clin. Cancer Res."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0006-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41416-018-0006-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:01:52Z","timestamp":1684602112000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-018-0006-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,13]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["6"],"URL":"https:\/\/doi.org\/10.1038\/s41416-018-0006-0","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,13]]},"assertion":[{"value":"3 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.D., E.H., F.L., D.B., P.H. were or are employees or consultants of Progen Pharmaceuticals Ltd or Zucero Therapeutics Ltd. The remaining authors declare that they have no competing of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}